Evidence map›Paper›PMID 28501760›Full record

ArticleNeoplasia (New York, N.Y.)2017

Stromal PDGFR-α Activation Enhances Matrix Stiffness, Impedes Mammary Ductal Development, and Accelerates Tumor Growth.

Anisha M Hammer, Gina M Sizemore, Vasudha C Shukla, Alex Avendano, Steven T Sizemore, Jonathan J Chang, Raleigh D Kladney, Maria C Cuitiño, Katie A Thies, Quinn Verfurth and 6 more

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Anisha M HammerThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA.
Gina M SizemoreThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA.
Vasudha C ShuklaDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Alex AvendanoDepartment of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Steven T SizemoreThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.
Jonathan J ChangDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Raleigh D KladneyThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Molecular Genetics, The Ohio State University, Columbus, OH 43210, USA.
Maria C CuitiñoThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Molecular Genetics, The Ohio State University, Columbus, OH 43210, USA.
Katie A ThiesThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA.
Quinn VerfurthThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Arnab ChakravartiThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.
Lisa D YeeThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Surgery, The Ohio State University, Columbus, OH, 43210, USA.
Gustavo LeoneThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Molecular Genetics, The Ohio State University, Columbus, OH 43210, USA.
Jonathan W SongThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Samir N GhadialiDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Michael C OstrowskiThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA. Electronic address: michael.ostrowski@osumc.edu.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Suppression of Mammary Tumorigenesis by Stromal p53P01CA097189 · NCI · OHIO STATE UNIVERSITY · PI ROSOL, THOMAS J · 2004 to 2016
$16.1M
NCI NIH HHS P01 CA097189NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

The extracellular matrix (ECM) is critical for mammary ductal development and differentiation, but how mammary fibroblasts regulate ECM remodeling remains to be elucidated. Herein, we used a mouse genetic model to activate platelet derived growth factor receptor-alpha (PDGFRα) specifically in the stroma. Hyperactivation of PDGFRα in the mammary stroma severely hindered pubertal mammary ductal morphogenesis, but did not interrupt the lobuloalveolar differentiation program. Increased stromal PDGFRα signaling induced mammary fat pad fibrosis with a corresponding increase in interstitial hyaluronic acid (HA) and collagen deposition. Mammary fibroblasts with PDGFRα hyperactivation also decreased hydraulic permeability of a collagen substrate in an in vitro microfluidic device assay, which was mitigated by inhibition of either PDGFRα or HA. Fibrosis seen in this model significantly increased the overall stiffness of the mammary gland as measured by atomic force microscopy. Further, mammary tumor cells injected orthotopically in the fat pads of mice with stromal activation of PDGFRα grew larger tumors compared to controls. Taken together, our data establish that aberrant stromal PDGFRα signaling disrupts ECM homeostasis during mammary gland development, resulting in increased mammary stiffness and increased potential for tumor growth.

Indexed as

AnimalsCell DifferentiationExtracellular MatrixFemaleGene Expression Regulation, DevelopmentalGene Expression Regulation, NeoplasticHumansHyaluronic AcidMammary Glands, AnimalMammary Glands, HumanMammary Neoplasms, AnimalMiceMorphogenesisReceptor, Platelet-Derived Growth Factor alphaSignal TransductionStromal CellsHyaluronic AcidReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID28501760
PMCPMC5440288
OpenAlexW2613553574

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.